A5076811048- Global Health and Surgery
- Health Systems, Economic Evaluations, Quality of Life
- Tuberculosis Research and Epidemiology
- Mosquito-borne diseases and control
- Malaria Research and Control
- Trypanosoma species research and implications
- Global Public Health Policies and Epidemiology
- Vaccine Coverage and Hesitancy
- Viral Infections and Outbreaks Research
- Parasites and Host Interactions
- Health and Medical Research Impacts
- Antifungal resistance and susceptibility
- Complement system in diseases
- Hepatitis C virus research
- Pharmaceutical Economics and Policy
- SARS-CoV-2 and COVID-19 Research
- Cardiomyopathy and Myosin Studies
- Poverty, Education, and Child Welfare
- Lysosomal Storage Disorders Research
- Vector-borne infectious diseases
- Hepatitis B Virus Studies
- Entomopathogenic Microorganisms in Pest Control
- HIV/AIDS Impact and Responses
- Signaling Pathways in Disease
- Mycobacterium research and diagnosis
European & Developing Countries Clinical Trials Partnership
2014-2024
Wellcome Trust
2000
John Radcliffe Hospital
1995-1997
Global research collaboration, through partnerships and networks, is an effective way to deliver highly impactful sustainable that collectively owned promoted for the global good. Many models exist North-South collaborations are built on trust balanced benefits. The European & Developing Countries Clinical Trials Partnership (EDCTP) model emphasises capacity development in clinical trials product-focused implementation research. To ensure effectiveness sustainability, requires a long-term...
Currently, no formal mechanisms or systematic approaches exist to inform developers of new vaccines the evidence anticipated facilitate global policy recommendations, before a vaccine candidate regulatory approval at end pre-licensure efficacy studies. Consequently, significant delays may result in introduction and uptake, while post-licensure data are generated support definitive decision. To address uncertainties evidence-to-recommendation needs mitigate risk between recommendation use,...
A small proportion of individuals infected with Plasmodium falciparum develop cerebral malaria. Why it affects some but not others is poorly understood. Since tumor necrosis factor (TNF) has been implicated strongly in the pathogenesis malaria, here we have compared different parasite isolates for their ability to induce TNF production by human mononuclear cells vitro. Wild were collected from 34 Gambian children malaria and 66 uncomplicated fever. Cerebral tended stimulate more than mild...
Scanning and transmission electron microscopy of Trypanosoma congolense epimastigotes attached to a plastic substratum shows them elaborate complex flagellum filament system plaque with highly organized structure. Non-ionic detergent extraction these cells that the resulting cytoskeletons remain plaque. The subpellicular corset microtubules can be removed by salt or Ca +2 treatment leaving axoneme, paraflagellar rod, associated filaments Neither treatments therefore plaque-associated...
The EDCTP community meets biennially to share research findings, plan new partnerships and collaborations, discuss maximising impact from EDCTP-funded research. In 2018, the Ninth Forum took place in Lisbon, Portugal, 17–21 September 2018. Lisbon meeting was largest international conference focusing on clinical poverty-related infectious diseases sub-Saharan Africa. It started with a strong commitment, European African member countries, for successor programme EDCTP2 (2014–2024). provided...
It is estimated that over 200 million people each year suffer debilitating attacks of malarial fever, and roughly 2 these episodes are fatal. The fever caused by tumour necrosis factor (TNF) other pyrogenic cytokines released the host immune system in response to products schizont rupture. TNF has anti-parasitic properties but excessive production thought play an important role pathogenesis cerebral malaria. This review summarizes recent attempts achieve molecular characterization parasite...
Background There are over ten vaccine candidates for tuberculosis (TB) in the clinical pipeline that require testing TB-prevalent populations. To accelerate development of TB vaccines, a directory trial centres was established sub-Saharan Africa (SSA) to assess capacity conducting late-stage trials. Methods vaccine-related parameters were identified, and SSA identified prioritized based on whether they had experience with or non-TB A survey sent centres, resulting presents their Centres as...
In November, 2023, 1118 delegates from 64 countries converged in Paris, France, for the 11th European & Developing Countries Clinical Trials Partnership (EDCTP) forum. Commemorating EDCTP's 20th anniversary, forum showcased findings EDCTP-funded projects and highlighted results of years investment conduct clinical research, networks, capacity strengthening, including advancement women science.
The Eighth Forum of the European & Developing Countries Clinical Trials Partnership took place in Lusaka, Zambia from 6 to 9 November 2016. biennial has grown size and recognition become one largest international conferences for presentation discussion frontier clinical research on poverty-related infectious diseases, as well capacity development including ethics, regulatory training initiatives sub-Saharan Africa. With support Union, EDCTP member countries other sponsors, conference...
The European and Developing Countries Clinical Trials Partnership (EDCTP) was established in 2003 to accelerate the development of medical interventions for tuberculosis (TB), human immunodeficiency virus (HIV) malaria, with a particular focus on Phase II III clinical trials. Between 2015, first EDCTP programme committed €65.6 million research TB TB-HIV co-infection. made significant contribution three elements DOTS control strategy, which mobilised African funding TB-related generated...
ABSTRACT Background There are over ten vaccine candidates for tuberculosis (TB) in the clinical pipeline that require testing TB-prevalent populations. To accelerate development of TB vaccines, a directory trial centres was established sub-Saharan Africa (SSA) to assess capacity conducting late-stage trials. Methods vaccine-related parameters were identified, and SSA identified prioritized based on whether they had experience with or non-TB A survey sent centres, resulting presents their...
Translating evidence from clinical trials to routine care can take many years, particularly in low-income and middle-income countries, delaying access life-saving or life-changing treatments. As few as one five evidence-based health interventions are incorporated into use, the average time lag between availability practice change is up 17 years.1Morris ZS Wooding S Grant J The answer what question: understanding lags translational research.J R Soc Med. 2011; 104: 510-520Crossref PubMed...